⌕
ANI Pharmaceuticals · ANIP · Nasdaq
Tenet 69 · Solid
Compare
$70.89−0.77%At closeTenet 69 · Solid
$70.89−0.55 (−0.77%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

ANI Pharmaceuticals (ANIP) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~42.2%/yr (FY21→FY25), net margin 8.9%, and free cash flow (~$171.4M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+68.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲43.8%
883.4
FY21→FY25CAGR +42.2%/yr
Net income ($M)—
78.3
one-off year: see footnoteCAGR —
Free cash flow ($M)▲258.7%
171.4
FY21→FY25CAGR +286.9%/yr
Diluted EPS—
3.32
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+68.5%

12.6mn → 21.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$13.8M

steady at 1.6% of revenue (−14.8% YoY).

Returns vs FCF
8%

$13.4M returned vs $171.4M of FCF in FY25. Buybacks + dividends covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)883.4Revenue−341.3COGS542.1Gross profit−51.7R&D−317.7SG&A111.1Op income−32.8Tax & other78.3Net income

9¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~4%FY21FY25

Over this window: gross 53.5% → 61.4%. Net margin 8.9% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,041,343.0883,366.0614,376.0486,816.0316,385.0216,136.0▲43.8%+42.2%
Cost of revenue
305,382.0341,310.0250,210.0181,513.0138,785.0100,610.0▲36.4%+35.7%
Gross profit
735,961.0542,056.0364,166.0305,303.0177,600.0115,526.0▲48.8%+47.2%
Research & development
50,605.051,664.044,581.034,286.022,318.011,369.0▲15.9%+46.0%
Selling, general & admin
342,968.0317,745.0249,636.0161,697.0124,044.084,294.0▲27.3%+39.3%
Total operating expenses
569,473.0430,963.0363,582.0258,332.0212,771.0155,319.0▲18.5%+29.1%
Operating incomefeeds ROC rank
166,488.0111,093.0584.046,971.0−35,283.0−39,793.0▲18922.8%—
Other income, net
−8,650.0−15,302.0−22,796.0−27,099.0−27,382.0−16,265.0——
Pretax income
157,838.095,791.0−22,212.019,872.0−62,665.0−56,058.0——
Income tax
40,996.017,454.0−3,690.01,093.0−14,769.0−13,455.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
116,842.078,337.0−18,522.018,779.0−47,896.0−42,603.0——
Per share
Diluted EPSbuyback-sensitive
4.983.32−1.040.85−3.05−3.40——
Diluted shares (mn)
21.6821.2319.3218.1916.2612.60▲9.9%+13.9%
Margins
Gross margin58th pct in Healthcare
70.7%61.4%59.3%62.7%56.1%53.5%▲2.1pp+7.9pp
Operating margin
16.0%12.6%0.1%9.6%−11.2%−18.4%▲12.5pp+31.0pp
Net margin70th pct in Healthcare
11.2%8.9%−3.0%3.9%−15.1%−19.7%▲11.9pp+28.6pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was 6% vs a 18% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was ANI Pharmaceuticals' revenue last fiscal year?

ANI Pharmaceuticals reported revenue of $883.4M in fiscal 2025, up 43.8% from fiscal 2024.

What was ANI Pharmaceuticals' net income?

ANI Pharmaceuticals reported net income of $78.3M in fiscal 2025, a net margin of 8.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.